The anatomic imaging modalities CT and MRI are currently the main imaging techniques used for localizing pheochromocytomas. Although the sensitivity of localizing tumors confined to the adrenals can reach 95% for CT or MRI (1), these modalities have limited specificity (2) because of metastatic and extraadrenal tumors. New imaging methods with higher specificity can play a crucial role in the diagnosis and localization of tumors.
PET with 18 F-FDG, the main radiopharmaceutical imaging agent in oncology, has been shown to be limited because of the lack of specificity for neuroendocrine tumors (3, 4) , which are generally well differentiated and slow growing. 11 C-epinephrine and 11 C-hydroxyephedrine catecholamine analogs developed for studying the sympathetic nervous system have provided good results (4-6); however, their widespread clinical use is limited by the short physical halflife of 11 C, which limits the acquisition time and requires onsite cyclotron production. 18 F-labeled radiopharmaceuticals with longer half-lives and active uptake in neuroendocrine cells can eliminate these limitations. 18 F-fluorodopamine has recently been evaluated for detection of pheochromocytoma and has provided improved results (7) (8) (9) . In this study, we evaluated 3,4-dihydroxy-6-18 F-fluoro-phenylalanine ( 18 F-FDOPA). A review of the literature revealed a few studies concentrating on 18 F-FDOPA PET of pheochromocytomas (Table 1) (10) (11) (12) (13) . The aims of this study were to evaluate the accuracy of PET and PET/CT with 18 F-FDOPA in detecting and localizing pheochromocytomas and assess the relationship between biochemical markers and tracer uptake (in the expectation that a better understanding of this relationship could improve the selection of patients for specific imaging studies). In addition, another aim of this study was to compare 18 F-FDOPA uptake in benign and malignant pheochromocytomas.
MATERIALS AND METHODS

Inclusion Criteria
We included all adult patients with suspected pheochromocytoma (based on clinical symptoms, biochemical results, or previous morphologic imaging studies) who had been referred to the Department of Nuclear Medicine for an 18 F-FDOPA PET scan before September 1, 2008.
After approval from the Institutional Review Board was obtained, we included 25 consecutive patients (9 men, 16 women; median age, 51 y; age range, 26-68 y) in a retrospective study.
Four patients (patients 10, 12, 13, and 21) had previously undergone resection of pheochromocytomas and were referred for evaluation of recurrence and possible additional sites of involvement ( Table 2 ). All patients underwent standardized whole-body 18 F-FDOPA PET or PET/CT studies. 18 F-FDOPA was synthesized according to a previously reported procedure (14, 15) .
PET Image Acquisition
Eleven patients underwent 18 F-FDOPA whole-body PET studies. PET was performed with an ECAT HR1 system (CTI/ Siemens). The patients were asked to fast for at least 6 h before the examination, to achieve optimal conditions for uptake of the radiopharmaceutical agent. A transmission scan of 3 min/bed position in 2-dimensional mode was acquired first. Subsequently, a median dose of 18 F-FDOPA (581 MBq; 4.7-10 MBq/kg; range, 537-625 MBq) was administered intravenously. After a 45-min uptake period, the emission scan was obtained in 3-dimensional mode for 4 min/per bed position. Eight to 10 bed positions with a 58.3-cm transaxial field of view were measured. The images were reconstructed with iterative techniques: maximum a posteriori maximization (16) for the transmission scan and ordered-subset expectation maximization consisting of 2 iterations with 8 subsets (17) for the emission scan. Corrections for attenuation and scatter were applied. No filtering before or after the scan was used. The final volume set had a transverse matrix size of 128 · 128, resulting in voxel size of 5.1 · 5.1 · 5.1 mm.
PET/CT Image Acquisition
Fourteen patients underwent 18 F-FDOPA whole-body PET/CT studies. The patients were asked to fast for at least 6 h before the examination. The last 5 patients received 200 mg of carbidopa 1 h before radiotracer injection to increase the tumor-to-background ratio of tracer uptake. A median dose of 18 F-FDOPA (385 MBq; 2-10 MBq/kg; range, 206-577 MBq) was injected. PET/CT was performed with a whole-body PET/CT scanner (Siemens/CTI Reveal). The CT was a dual-slice system. Diagnostic-quality CT images were acquired, with the following parameters: 130 kVp, 120 mAÁs, 1-s rotation, 4-mm section collimation, 5-mm section thickness, and 10-mm feed per rotation with a pitch of 1.3 mm/s. CT images were acquired after intravenous injection of iohexol (110-120 mL) (Omnipaque 350; GE Healthcare), except for 1 patient, who underwent recent 18 F-FDG PET/CT with intravenous contrast in an outside facility. The PET component was a lutetium oxyorthosilicate detector, 3-dimensional system. After the whole-body CT scan, PET images were obtained 60 min after injection and acquisition time per bed position was 1-5 min, depending on patient body weight, as previously published (18, 19) . Emission scans in patients weighing less than 59 kg were acquired for 1 min/bed position, and scans in those patients weighing more than 91 kg were acquired for 5 min. Images were acquired at multiple bed positions from approximately the patients' middle thighs to the base of the skull. To minimize misregistration, CT and PET were acquired during shallow breathing (20) . Image reconstruction was performed by using an iterative procedure (ordered-subset expectation maximization, 2 iterations, 8 subsets) and postinjection CT-based photon attenuation correction.
Interpretation of PET and PET/CT Studies
PET and PET/CT images were interpreted by 2 board-certified nuclear medicine physicians using image analysis and fusion software (Mirada; CTI). The interpreters were unaware of the patients' clinical history, laboratory results, and prior imaging studies. The locations of abnormal tracer uptake were recorded, and any visible uptake above normal background was considered abnormal. The sizes of the lesions were measured on PET/CT images by 2 investigators. A 3-dimensional region of interest was manually drawn around areas of abnormal uptake, and the maximum standardized uptake value (SUVmax) was determined. Images were interpreted as positive or negative for pheochromocytoma or paraganglioma by consensus.
Histopathology
The gold standard for the diagnosis of pheochromocytoma is histopathologic evaluation of 4-mm-thick, hematoxylin-and eosinstained sections prepared from representative, paraffin-embedded tissue sections of surgical specimens after fixation in 10% buffered formalin. Confirmatory immunohistochemical staining is performed using standard procedures in a DAKO autostainer using antisera against S-100 (1:500; DAKO), chromogranin (1:1,000; DAKO), and synaptophysin (1:100; DAKO). Pheochromocytomas exhibit positivity for chromogranin and synaptophysin. In addition, S-100 immunostain highlights the presence of sustentacular cells that typically surround nests of tumor cells.
Composite Reference
Because histologic verification, which would have been the most accurate reference standard, was not feasible in all cases, a combination of follow-up evaluations, laboratory findings, and other imaging modalities was used as the reference standard to determine the accuracy of 18 F-FDOPA PET and PET/CT in the diagnosis of pheochromocytoma.
Statistics
The Fisher exact test was used to compare the number of true and false findings in 18 F-FDOPA PET and PET/CT studies. Sensitivity, specificity, and accuracy of combined data were calculated using the composite reference standard. For correlations between SUVmax of the 18 F-FDOPA uptake in the tumors and biochemical parameters, the Spearman nonparametric correlation coefficient was calculated. The SUVmax of benign and malignant tumors was compared using the Mann-Whitney nonparametric analysis. A 2-sided P value of less than 0.05 was considered significant.
RESULTS
Eleven patients underwent 18 F-FDOPA PET studies, and 14 patients underwent 18 F-FDOPA PET/CT studies. The examiners, who were unaware of the clinical findings and laboratory results, detected and localized lesions with abnormally elevated tracer activity in 3 PET and 8 PET/CT studies ( Table 2 ; Figs. 1-5). These lesions had an SUVmax ranging from 2.3 to 34.9 (median, 10), and the maximum diameter of the lesions ranged from 33 to 87 mm (median, 55 mm) for the PET/CT studies.
A subsequent review of the studies revealed 2 falsenegatives cases. A positive lesion measuring 13 · 5 mm with an SUVmax of 1.96 was detected in the right adrenal bed, adjacent to the liver in 1 patient (patient 10, Fig. 1 ), but had not been detected in the visual evaluation. This patient had undergone surgical resection previously. This case was considered false-negative in the analysis. In another patient with typical clinical findings and strongly positive biochemical markers (patient 1), multiple imaging studies including PET, CT, MRI, and metaiodobenzylguanidine (MIBG) did not visualize any lesion. Because of the lack of tumor localization, this patient did not undergo surgery. Subsequent 131 I-MIBG therapy led to some improvement in symptoms, and the case was considered false-negative for pheochromocytoma.
One of the patients (patient 19, Fig. 2 ) with positive biochemical and PET/CT findings had extensive retroper-itoneal involvement along the sympathetic chain extending into the caudate lobe of the liver and engulfing the inferior vena cava. This tumor was deemed unresectable by the tumor board. This case was considered true-positive without histologic confirmation.
Seventeen of the 25 patients (68%) underwent surgery. Histologic evaluation of the lesions revealed pheochromocytoma and paraganglioma in 11 cases (44%) (patients 8-10, 12-14, 17, 20-22, and 25; Figs. 3 and 4) , nonchromaffin cell tumors in 5 cases, adrenal cortical adenomas in 3 cases (12%) (patients 15, 23, and 24; Fig. 5 ), Castleman disease in 1 case (patient 16), metastatic mucinous adenocarcinoma of lung primary in 1 case (patient 18), and normal duodenal tissue in 1 case (patient 11) ( Table 2 ). The remaining patients had a minimum of 4 y of clinical follow-up.
Statistical analysis of the visual interpretation of PET and PET/CT studies using the Fisher exact test did not show statistically significant differences between the 2 modalities (P 5 1). Therefore, further analysis was performed on combined data. The sensitivity of 18 F-FDOPA PET and PET/CT studies for diagnosis of chromaffin cell tumors was 84.6% (95% confidence interval, 53.7%297.3%) on the basis of findings in the 11 histologically confirmed cases and 2 false-negative cases (patients 1 and 10). Because there was no false-positive finding, the specificity was 100% (95% confidence interval, 69.9%2100%) ( Table 3) .
Biochemical work-up of 15 patients was available for this study. Ten patients (67%) had significantly elevated biochemical markers that were diagnostic of pheochromo- cytoma (21, 22) . Genetic analysis was performed on 4 patients, revealing a succinate dehydrogenase complex subunit B mutation for patients 13 and 21, von HippelLindau mutation for patient 14, and no detectable genetic abnormality for patient 12. To evaluate whether uptake of 18 F-FDOPA in pheochromocytoma lesions is independent of plasma or urinary biochemical levels, correlation between SUVmax of the lesions and biochemical levels was analyzed. Spearman nonparametric analysis did not demonstrate a statistically significant correlation, at the 0.05 level, between SUVmax of the tumors and plasma or urinary biochemical measurements (Tables 4 and 5 ). This lack of correlation confirms that the SUVmax of the tumors represents an independent indicator of presence of disease.
Three patients (patients 10, 12, and 13) were diagnosed with malignant pheochromocytomas. Malignant pheochromocytomas were defined as tumors presenting either initially or subsequently with foci outside known chromaffin sites. All 3 patients had undergone surgical resection of the primary lesions before this study. Although the metastatic lesions, compared with the benign tumors, detected on the initial 18 F-FDOPA PET/CT examinations of all 3 patients demonstrated relatively low 18 F-FDOPA uptake, a subsequent 18 F-FDOPA PET/CT study of 1 of the patients (patient 10) revealed multiple foci of intense 18 
DISCUSSION
This study demonstrated no false-positive findings. Two false-negative cases were identified. One patient underwent a PET/CT study that was performed after surgery for evaluation of recurrence. Review of this case revealed that a 13 · 5 mm lesion with an SUVmax of 1.96 in the right adrenal bed had been missed on the initial visual analysis. The second false-negative finding occurred in a patient with typical clinical manifestations who had the highest levels of biochemical markers in our study group. Evaluation of this patient with several imaging modalities did not detect any lesion. However, subsequent treatment of this patient with 131 I-MIBG led to partial improvement of symptoms. Failure in detection of the tumor could be secondary to several factors, including the small size of the lesion; location of the tumor in or near organs with high physiologic 18 F-FDOPA activity such as the pancreas, biliary and urinary systems; or true loss of 18 F-FDOPA uptake due to a general process of dedifferentiation as it has been recognized in 123 I-MIBG uptake (23) .
This study demonstrates multiple advantages of 18 F-FDOPA PET and PET/CT in preoperative localization of lesions and confirmation of diagnosis in suspected cases of pheochromocytoma. Catecholamine-based testing can be confounded by several medications that are known to yield false-positive results (24) . Often patients are unable to stop taking these medications (e.g., psychotropic medications), and for the patients, the only biochemical test available is chromogranin A, which is neither sensitive nor specific. 18 F-FDOPA PET/CT eliminates this conundrum and diagnoses these patients without a need for the patients to discontinue their medications. The patients with borderline elevated catecholamines constitute another diagnostic challenge. Some investigators have recommended clonidine suppression testing (25) , but this is labor-intensive and would require personnel training to be performed accurately. Our data show that 18 F-FDOPA PET is a reliable functional imaging modality that can be used as part of the diagnostic work-up in cases in which all previous tests did not lead to a definite diagnosis, without the need for clonidine suppression testing. In the appropriate clinical context, 18 F-FDOPA PET can confirm or reject the diagnosis of pheochromocytoma. This ability of 18 F-FDOPA PET carries major clinical impact on presurgical preparation of the patients and surgical planning.
Nonparametric statistical analysis of our data using the Spearman correlation coefficient test demonstrated that the SUVmax of the tumors did not have a statistically significant correlation with biochemical assays in positive cases. This result can be explained by complex pathways and kinetics of the biochemical processes. SUVmax represents tumoral radiopharmaceutical accumulation, which depends on the uptake rate of 18 F-FDOPA, biochemical reactions, and the rate of active or passive release of biochemical products. Plasma levels of biochemical components and 24-h urinary levels are mainly secondary to the rate of production, release, and clearance. This characteristic implies that 18 F-FDOPA PET can be used for diagnosis of suspected cases, independent of plasma and urinary catecholamine levels.
PET with 18 F-FDOPA is based on the ability of neuroendocrine tumors to take up, decarboxylate, and store amino acids, such as DOPA (26) (27) (28) . The special advantage of 18 F-FDOPA PET, compared with conventional scintigraphic methods, is the lack of accumulation of 18 F-FDOPA in the normal adrenal glands, which may occur in as many as 32%275% of patients 24 h after administration of 131 I-MIBG (29, 30) . Furthermore, the higher spatial resolution of PET enables detection of small lesions and metastatic lymphadenopathies. PET can be performed shortly after the administration of 18 F-FDOPA, as opposed to waiting the 24-48 h necessary for 131 I-MIBG scanning, and provides tomographic images instead of planar images. The selective tracer accumulation in the target cells, low background uptake-in combination with higher resolutionand 3-dimensional acquisition yield excellent-quality whole-body images that significantly improve image interpretation. In addition, discontinuation of medications is not necessary for 18 F-FDOPA PET. Interference of medications with 18 F-FDOPA uptake, which is a well-known phenomenon in MIBG imaging, has not been reported. In our study, all PET and PET/CT studies were performed while the patients continued their medications without interruption. Another advantage of 18 F-FDOPA PET is less radiation exposure (31, 32) ; in conventional 131 I-MIBG, radiation exposure necessitates thyroid blocking with administration of iodine.
This study has several limitations. Because of the low prevalence of the disease, we included only 3 patients with metastatic pheochromocytoma. Thus, future studies are needed to investigate the value of 18 F-FDOPA PET in patients with metastatic disease. Second, the whole-body biodistribution of 18 F-FDOPA with relatively high uptake in the pancreas, biliary and urinary systems could induce image misinterpretations. For instance, normal pancreatic tracer activity might spill over or project onto the region of the adrenals, causing a false-positive interpretation. Conversely, abnormal adrenal uptake might be masked by physiologic background activity, causing false-negative scan interpretations. However, combined PET/CT can probably reduce or even eliminate this source of error. Third, 1 study has reported that medication in advance with carbidopa may increase tumor uptake of 18 F-FDOPA (11). However, this study reported a moderate increase in sensitivity with the addition of carbidopa from 55.6% to 66.7%. Finally, the current study did not attempt a comparison with other probes such as amino acid analogs or MIBG that could be used for imaging of neuroendocrine tumors. Therefore, it remains unknown whether 18 F-FDOPA is equivalent or superior to these other approaches.
CONCLUSION
On the basis of these results, 18 F-FDOPA PET and PET/ CT are valuable tools not only for improving detectability but also for precisely localizing the tumors, especially when they arise from the adrenal glands.
